Logo Cepheid
Maggiori informazioni
Località/Lingua

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Località/Lingua

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Maggiori informazioni
Maggiori informazioni

Xpert® Breast Cancer STRAT4

Order Now
STRAT4 computer generated depiction.

Valutazione standardizzata basata su mRNA dei biomarcatori ESR1, PGR, ERBB2 e MKi67 del cancro della mammella in meno di due ore.

L’esigenza

an ill woman listens to a physician
I risultati relativi ai biomarcatori del cancro della mammella ER/PGR/HER2/Ki-67 devono ritenersi affidabili ed obiettivi
  • I clinici necessitano di una valutazione estremamente affidabile dei biomarcatori ER/PGR/HER2/Ki-67 nel campione FFPE del tessuto tumorale.
  • In base ai dati delle linee guida il 5% dei risultati HER2 con metodica IHC è di ambigua interpretazione.1
  • I risultati HER2 IHC2+ equivoci richiedono conferma mediante metodica FISH.1-4
  • La variabilità della tecnica e la mancata standardizzazione determina una percentuale di risultati ER e PGR intorno al 20%.5
  • Gli score Ki-67 IHC si discostano a seconda della metodica per la mancanza di standardizzazione.6
(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2)Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues’ Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.

La soluzione

a male and a female researchers scanning cepheid test cartridges
Xpert Breast Cancer STRAT4 supports standardized ER/PGR/HER2/Ki‑67 mRNA assessment in less than 2 hours.
  • Xpert Breast Cancer STRAT4 fornisce un risultato semi-quantitativo dei livelli di mRNA per ER/PGR/HER2/Ki-67 da sezioni FFPE di pazienti con carcinoma invasivo della mammella
    • Il gene di riferimento CYFIP1* viene utilizzato per la normalizzazione del campione
    • Ogni test include tre controlli
    • Il report generato dal software offre un'interpretazione obiettiva e semplice dei risultati
CYFIP1: Proteina citoplasmatica 1che interagisce con FMR1

L’impatto

a smiling female doctor attends an elderly woman
  • Fast, clear, and accurate results by STRAT4 can help laboratories in diverse settings address various challenges with IHC/ISH testing to aid in the clinical evaluation of patients. 6
  • May facilitate a cost-efficient, quick, easy, and quality solution in labs facing challenges with IHC.7-9
  • Enables decentralized testing that doesn’t require a PCR laboratory to support breast cancer testing in low- and middle-income countries. 6.7.9
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.
(7) Marcellin Mugabe, Kenneth E Ho, Deo Ruhangaza, Dan Milner, Belson Rugwizangoga, Victor C Chu, Natalie C Wu, Annaliza Rizo, Jodi M Weidler, Wendy Wong, Michael Bates, Jane E Brock, Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country, American Journal of Clinical Pathology, Volume 156, Issue 5, November 2021, Pages 766–776, https://doi.org/10.1093/ajcp/aqab016
(8) El Aje, R, Naya A, Khoaja A, Zaid Y, Oudghiri M, Weidler J, and Karkouri M. A Study Comparing Immunohistochemistry, Fluorescence in situ hybridization, GeneXpert® Breast Cancer STRAT4 Assay for Determining Hormone Receptor, Human Epidermal Growth Factor Receptor 2, Ki67 Status in Invasive Breast Carcinomain Moroccan women. Progress in Microbes and Molecular Biology. 2023; 6, 1; a0000332. doi: 10.36877/pmmb.a0000332.
(9) Erfani P et al. Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert® mRNA expression assay. Bull World Health Organ 2023;101:10–19 | doi: http://dx.doi.org/10.2471/BLT.22.288800 The Impact The Need The Solution Breast cancer in women is the leading cancer worldwide, with approximately 2.3 million new breast cancer cases every year.

Per risultati migliori

Maggiori informazioni
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web